Insulin resistance in thyroid disorders: association between anti-TPO and HOMA-IR

Hari Krishnamurthy; Thushani Siriwardhane; Karthik Krishna; Qi Song; Vasanth Jayaraman; Tianhao Wang; Kang Bei; John J. Rajasekaran

doi:10.1101/2023.06.06.23291013

ABSTRACT

The association of thyroid disease and diabetes has been classically described. However, the comorbidity of thyroid disparities and insulin resistance is not frequently assessed, especially the sequence of the occurrence of these markers. We performed a retrospective analysis to evaluate the association between thyroid disease and diabetes markers. We further investigated the sequence of occurrence of thyroid and diabetes markers to identify any predictive capabilities of these markers. We evaluated 32787 subjects who were classified based on their serum thyroid hormones and autoantibody levels. Our general prevalence results showed that HOMA-IR was elevated in overt hypothyroid subjects (43.7%) and overt hyperthyroid subjects (42.2%). HbA1C was elevated in subclinical hypothyroid subjects (19.2%), overt hypothyroid subjects (22.3%) and overt hyperthyroid subjects (21.2%). Glucose was significantly elevated in subclinical hypothyroid subjects (24.2%) and overt hyperthyroid subjects (31.0%). Insulin was only significantly elevated in overt hypothyroid subjects (15.1%). Interestingly, we found that 70.3% of subjects who had their HOMA-IR score escalated from negative (HOMA-IR<2.7) to positive (HOMA-IR>2.7) during their multiple visits had anti-TPO 369 (±242) days prior to the onset of this change. Our comprehensive study provided evidence that the presence of anti-TPO may suggest a predictive role in developing insulin resistance later in life.

Strengths and limitations of the study

The strength of our study is the large population size including a larger set of markers from both thyroid disease and diabetes.
The limitation in our study is the distorted male and female ratio.

Competing Interest Statement

TS and QS are paid employees of Vibrant America LLC. KK, VJ, TW, KB, HK, JJR are paid employees of Vibrant Sciences LLC. Vibrant Sciences or Vibrant America could benefit from increased testing based on the results. There are no patents, products in development, or marketed products to declare.

Funding Statement

Vibrant America provided funding for this study in the form of salaries for authors [TS, QS, KK, VJ, TW, KB, HK, JJR]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted under the ethical principles that have their origins in the Declaration of Helsinki. This is a retrospective study conducted from remnant samples of individuals that visited Vibrant Clinical Lab for routine tests. The IRB (WCG IRB (Western Institutional Review Board) (#1-1098539-1)) exemption enabled us to use the de-identified laboratory data for the retrospective analysis. The data and materials in this manuscript have not been published elsewhere and are not under consideration by another journal.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes